Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous
success treating B cell malignancies; however, some patients fail to respond due to poor …
success treating B cell malignancies; however, some patients fail to respond due to poor …
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models
JH Shin, HB Park, YM Oh, DP Lim… - Blood, The Journal …, 2012 - ashpublications.org
Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) has been known to be a strong
tolerance-inducing inhibitory receptor on T-cell surface. Systemic blocking of CTLA4 function …
tolerance-inducing inhibitory receptor on T-cell surface. Systemic blocking of CTLA4 function …
CTLA-4 suppresses proximal TCR signaling in resting human CD4+ T cells by inhibiting ZAP-70 Tyr319 phosphorylation: a potential role for tyrosine phosphatases
C Guntermann, DR Alexander - The Journal of Immunology, 2002 - journals.aai.org
The balance between positive and negative signals plays a key role in determining T cell
function. CTL-associated Ag-4 is a surface receptor that can inhibit T cell responses induced …
function. CTL-associated Ag-4 is a surface receptor that can inhibit T cell responses induced …
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR
D Stenger, TA Stief, T Kaeuferle… - Blood, The Journal …, 2020 - ashpublications.org
Anti-CD19 chimeric antigen receptor (CAR) T cells showed significant antileukemic activity
in B-precursor acute lymphoblastic leukemia (ALL). Allogeneic, HLA-mismatched off-the …
in B-precursor acute lymphoblastic leukemia (ALL). Allogeneic, HLA-mismatched off-the …
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
Abstract Anti-CTLA-4 monoclonal antibodies (mAbs) confer a cancer immunotherapeutic
effect (CITE) but cause severe immunotherapy-related adverse events (irAE). Targeting …
effect (CITE) but cause severe immunotherapy-related adverse events (irAE). Targeting …
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
B Kavanagh, S O'Brien, D Lee, Y Hou… - Blood, The Journal …, 2008 - ashpublications.org
Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) delivers inhibitory signals to activated
T cells. CTLA4 is constitutively expressed on regulatory CD4+ T cells (Tregs), but its role in …
T cells. CTLA4 is constitutively expressed on regulatory CD4+ T cells (Tregs), but its role in …
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Chimeric antigen receptor (CAR)–expressing T cells induce durable remissions in patients
with relapsed/refractory B cell malignancies. CARs are synthetic constructs that, when …
with relapsed/refractory B cell malignancies. CARs are synthetic constructs that, when …
[HTML][HTML] Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies
LQC Hill, RH Rouce, TS Smith, L Yang, M Srinivasan… - Blood, 2019 - Elsevier
Introduction: We describe a Phase I dose escalation study (NCT03081910) of autologous
CD5-directed chimeric antigen receptor T cell (CD5 CAR T) therapy for relapsed or …
CD5-directed chimeric antigen receptor T cell (CD5 CAR T) therapy for relapsed or …
Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection
J Jiang, J Chen, C Liao, Y Duan, Y Wang, K Shang… - Leukemia, 2023 - nature.com
CAR-T therapies to treat T-cell malignancies face unique hurdles. Normal and malignant T
cells usually express the same target for CAR, leading to fratricide. CAR-T cells targeting …
cells usually express the same target for CAR, leading to fratricide. CAR-T cells targeting …
Tumor-targeted human T cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition
M Condomines, J Arnason, R Benjamin, G Gunset… - PloS one, 2015 - journals.plos.org
Adoptive T cell therapy represents a promising treatment for cancer. Human T cells
engineered to express a chimeric antigen receptor (CAR) recognize and kill tumor cells in a …
engineered to express a chimeric antigen receptor (CAR) recognize and kill tumor cells in a …